Literature DB >> 9527265

Sentinel node biopsy in breast cancer.

J M Barnwell1, M A Arredondo, D Kollmorgen, J F Gibbs, D Lamonica, W Carson, P Zhang, J Winston, S B Edge.   

Abstract

BACKGROUND: Sentinel lymph node biopsy (SNB) in breast cancer may be used in place of axillary lymph node dissection (ALND) if SNB accurately stages the axilla. This study assessed the success and accuracy of axillary SNB with isosulfan blue (ISB) and technetium-99 sulfur colloid (TSC) compared to ALND.
METHODS: Forty-two women with T1 or T2 breast cancer underwent SNB and ALND. Sixty to 90 minutes before anesthetic induction, a mixture of 3 mL ISB and 1 mCi TSC was injected around the primary cancer or prior biopsy site. Intraoperatively, the SLN was identified using a gamma detector (Neoprobe 1000) or by visualization of the blue-stained lymph node and afferent lymphatics. The SLN was excised separately, and a level I/II ALND was completed. The histologic findings of the axillary contents and SLN were compared.
RESULTS: An axillary SLN was found in 38 of 42 (90%) cases. SLN localization rate and predictive value were the same for women who had and those who had not undergone excisional biopsy before the date of SNB. Fifteen of 42 (36%) patients had lymph node metastases. The SLN was positive in all women with axillary metastases (negative predictive value, 100%).
CONCLUSIONS: If confirmed by larger series, a negative SNB may eliminate the need for ALND for select women with breast cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9527265     DOI: 10.1007/bf02303845

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  Credentialing for breast lymphatic mapping: how many cases are enough?

Authors:  H S Cody; A D Hill; K N Tran; M F Brennan; P I Borgen
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

Review 2.  Axillary staging of breast cancer and the sentinel node.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

3.  MR imaging-guided axillary node biopsy for breast cancer: initial findings.

Authors:  Takuji Yamagami; Sachiko Yuen; Kiyoshi Sawai; Tsunehiko Nishimura
Journal:  Eur Radiol       Date:  2003-06-14       Impact factor: 5.315

Review 4.  Sentinel lymph node mapping for primary breast cancer.

Authors:  Lori L Wilson; Armando E Giuliano
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

5.  Predictors for nonsentinel node involvement in breast cancer patients with micrometastases in the sentinel lymph node.

Authors:  Archana Ganaraj; Joseph A Kuhn; Ronald C Jones; Michael D Grant; Valerie R Andrews; Sally M Knox; Georges J Netto; Basel Altrabulsi; Sheryl A Livingston; Todd M McCarty
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

6.  Sentinel node biopsy in early breast cancer in Taiwan.

Authors:  Jyh-Cherng Yu; Giu-Cheng Hsu; Yao-Chi Liu; Lai-Fa Sheu; Su-Hui Li; Tsu-Yi Chao
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

7.  Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study.

Authors:  K M McMasters; S L Wong; R C Martin; C Chao; T M Tuttle; R D Noyes; D J Carlson; A L Laidley; T Q McGlothin; P B Ley; C M Brown; R L Glaser; R E Pennington; P S Turk; D Simpson; P B Cerrito; M J Edwards
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

8.  Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  1999-12       Impact factor: 3.411

9.  Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy.

Authors:  J Cantin; H Scarth; M Levine; M Hugi
Journal:  CMAJ       Date:  2001-07-24       Impact factor: 8.262

10.  Subareolar blue dye only injection sentinel lymph node biopsy could reduce the numbers of standard axillary lymph node dissection in environments without access to nuclear medicine.

Authors:  Andreas Kavallaris; Oumar Camara; Ingo B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2007-11-20       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.